Chronic Lymphocytic Leukemia Podcasts This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Treatment options for co-morbid chronic lymphocytic leukemia (CLL) patients
Barbara Eichhorst, MD from University of Cologne, Cologne, Germany discussing treatment options for co-morbid chronic lymphocytic leukemia (CLL) patients. These individuals face frequent medical probl... Author: VJHemOnc Added: 07/05/2016 (Source: Oncology Tube)
Source: Oncology Tube - July 5, 2016 Category: Cancer & Oncology Source Type: podcasts

EHA 2016: Alternative treatment options for CLL
Klaus Okkenhaug, PhD from Babraham Institute, Cambridge, UK discusses alternative options for the treatment for chronic lymphocytic leukemia (CLL). Similar to idelalisib are the SYK inhibitors which a... Author: VJHemOnc Added: 06/30/2016 (Source: Oncology Tube)
Source: Oncology Tube - June 30, 2016 Category: Cancer & Oncology Source Type: podcasts

EHA 2016: The iwCLL 2017 meeting
Michael Hallek, MD from the University of Cologne, Cologne, Germany gives an overview of the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) meeting, wich will be held in New York City ... Author: VJHemOnc Added: 06/30/2016 (Source: Oncology Tube)
Source: Oncology Tube - June 30, 2016 Category: Cancer & Oncology Source Type: podcasts

Results of Phase II trial to assess the efficacy and safety of idelalisib
" Andrew Davies, MRCP, PhD from University of Southampton, Southampton, UK discusses his participation in the joint symposia regarding high risk chronic lymphocytic leukemia (CLL) and follicular... Author: VJHemOnc Added: 06/28/2016 (Source: Oncology Tube)
Source: Oncology Tube - June 28, 2016 Category: Cancer & Oncology Source Type: podcasts

EHA 2016: Current thought on treating chronic lymphocytic leukemia
Jeffrey Jones, MD, MPH from the Ohio State University, Columbus, OH discusses the current thought on treating relapsed and refractory chronic lymphocytic leukemia (CLL). This is an area where one can ... Author: VJHemOnc Added: 06/24/2016 (Source: Oncology Tube)
Source: Oncology Tube - June 24, 2016 Category: Cancer & Oncology Source Type: podcasts

EHA 2016: Is CLL curable today?
Michael Hallek, MD from the University of Cologne, Cologne, Germany discusses the debate around whether chronic lymphocytic leukemia (CLL) is curable. Prof Hallek argues that it is possible to cure CL... Author: VJHemOnc Added: 06/24/2016 (Source: Oncology Tube)
Source: Oncology Tube - June 24, 2016 Category: Cancer & Oncology Source Type: podcasts

The importance of diagnostic testing in CLL
Anna Schuh, MD, PhD, from the University of Oxford, discusses the importance of genomic analysis in chronic lymphocytic leukemia (CLL) in the clinic. According to Dr Schuh, the mutation analysis of TP... Author: VJHemOnc Added: 06/24/2016 (Source: Oncology Tube)
Source: Oncology Tube - June 24, 2016 Category: Cancer & Oncology Source Type: podcasts

The importance of diagnostic testing in CLL
Anna Schuh, MD, PhD, from the University of Oxford, discusses the importance of genomic analysis in chronic lymphocytic leukemia (CLL) in the clinic. According to Dr Schuh, the mutation analysis of TP... Author: VJHemOnc Added: 06/23/2016 (Source: Oncology Tube)
Source: Oncology Tube - June 23, 2016 Category: Cancer & Oncology Source Type: podcasts

CLL, Chronic Lymphocytic Leukemia - What is the significance of IGHV mutations and how are they assessed?
CLL, Chronic Lymphocytic Leukemia, What is the significance of IGHV mutations and how they are assessed. Presented by Jennifer Brown, M.D., Ph.D., Director of the CLL Center and the Dana-Farber Cancer... Author: cancergrace Added: 06/22/2016 (Source: Oncology Tube)
Source: Oncology Tube - June 22, 2016 Category: Cancer & Oncology Source Type: podcasts

EHA 2016: Side effects of novel drugs and managing patient expectations in CLL
Paolo Ghia, MD, PhD from the San Raffaele Scientific Institute, Milan, Italy discusses the side effects of novel drugs in chronic lymphocytic leukemia (CLL). According to Dr Ghia, the toxicity profile... Author: VJHemOnc Added: 06/21/2016 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2016 Category: Cancer & Oncology Source Type: podcasts

EHA 2016: Why drug combinations are the future of treatment in CLL
Paolo Ghia, MD, PhD from the San Raffaele Scientific Institute, Milan, Italy discusses drug combinations for the treatment of chronic lymphocytic leukemia (CLL). In particular, Dr Ghia talks about the... Author: VJHemOnc Added: 06/21/2016 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2016 Category: Cancer & Oncology Source Type: podcasts

EHA 2016: Why venetoclax is a promising new drug for CLL
Paolo Ghia, MD, PhD from the San Raffaele Scientific Institute, Milan, Italy talks about venetoclax for chronic lymphocytic leukemia (CLL). Venetoclax has recently been approved by the FDA to treat re... Author: VJHemOnc Added: 06/21/2016 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2016 Category: Cancer & Oncology Source Type: podcasts

EHA 2016: Why the rapid development of new drugs poses new challenges
Kostas Stamatopoulos, MD, PhD from CERTH Institute of Applied Biosciences, Thessaloniki, Greece discusses the issues associated with the rapid development of new drugs in chronic lymphocytic leukemia ... Author: VJHemOnc Added: 06/21/2016 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2016 Category: Cancer & Oncology Source Type: podcasts

EHA 2016: The stratification of CLL patients and implications for clinical practice
Paolo Ghia, MD, PhD from the San Raffaele Scientific Institute, Milan, Italy talks about the stratification of chronic lymphocytic leukemia (CLL) patients at the European Hematology Association (EHA) ... Author: VJHemOnc Added: 06/21/2016 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2016 Category: Cancer & Oncology Source Type: podcasts

EHA 2016: Why MRD is a hot topic in CLL and how it should be used
Paolo Ghia, MD, PhD from the San Raffaele Scientific Institute, Milan, Italy discusses minimal residual disease (MRD) negativity in chronic lymphocytic leukemia (CLL) at the European Hematology Associ... Author: VJHemOnc Added: 06/21/2016 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2016 Category: Cancer & Oncology Source Type: podcasts